Akero Therapeutics
AKRO54.6500.00% ( 0.000 )
Akero Therapeutics (AKRO)
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 54.650
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 58.400
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Akero Therapeutics Analyst Rating
View MoreForecast & Rating
Nov 13, 2025Price forecast
--100.00%
Forecast & RatingHold
7analysts
- Strong buy14.29%
- Buy0.00%
- Hold85.71%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · Apr 20 at 09:57 PM
22:54 ETCadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
- prnewswire · Apr 14 at 03:14 PM
16:13 ETAre KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders?
- prnewswire · Apr 6 at 10:32 PM
23:28 ETAkeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L) 1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
- prnewswire · Mar 31 at 04:42 AM
05:40 ETIvonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
- prnewswire · Mar 15 at 09:07 PM
22:05 ETAkeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
- Tip Ranks · Mar 12 at 11:34 AM
Aker BioMarine Registers Share Capital Increase from Employee Share Program
